MIMICS-2 at 1 year: 3D stent meets safety & effectiveness goals
Feb. 11, 2018- By: Caitlin E.Cox
Courtesy ofVeryan Medical Ltd.
The TCTMD reports on Timothy Sullivan`s presentation at the International Symposium on Endovascular Therapy. In terms of 12-month primary patency, the strategy of "natural swirling flow is an alternative to antiproliferative drugs," the researcher says.
Most popular related searches
Stay in the loop!
Select your areas of interest to receive industry updates.